The Show Must Go On

An Update on Clinical Experiences and Clinical Studies on Novel Pharmaceutical Developments for the Treatment of Atopic Dermatitis

Tatjana Honstein; Thomas Werfel


Curr Opin Allergy Clin Immunol. 2020;20(4):386-394. 

In This Article

Targeting Thymic Stromal Lymphopoietin for the Treatment of Atopic Dermatitis With Tezepelumab

Like IL-31, the epithelial cytokine thymic stromal lymphopoietin (TSLP) has both inflammatory and direct itch-inducing effects, thus representing a further interesting target structure for the treatment of atopic dermatitis. A first proof-of-concept study with the anti-TSLP antibody tezepelumab led to mild rather clinical effects. There was a trend of improvement of the skin compared with placebo but the primary study objective, and itch reduction was not significant at all visits in this placebo-controlled study. It is possible that topical corticosteroids allowed in the placebo group were responsible for a relatively high placebo effect in this study.[34] The antibody is currently further investigated with another study design.